John Markels - 05 Jun 2026 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Reporting relationship: Director
Issuer ticker: ARCT
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:01:18 UTC
Prior SEC filing: 16 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Ilan Katz, attorney-in-fact

Key filing fact

John Markels filed Form 4 for Arcturus Therapeutics Holdings Inc. (ARCT) on 15 Jun 2026.

Key facts

This page summarizes John Markels's Form 4 filing for Arcturus Therapeutics Holdings Inc. (ARCT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 17:01.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001803424 Primary reporting owner

Markels John

Relationship: Director
Address: C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10285 SCIENCE CENTER DRIVE, SAN DIEGO
Signature: /s/ Ilan Katz, attorney-in-fact
Signature date: 15 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARCT transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +15,000
Change %
Price: $0.000000^*
Shares after: 15,000
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $7.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.